Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Long-Term Deferred Tax (2018 - 2020)

Historic Long-Term Deferred Tax for Protagonist Therapeutics (PTGX) over the last 3 years, with Q1 2020 value amounting to $1.1 million.

  • Protagonist Therapeutics' Long-Term Deferred Tax rose 12635.98% to $1.1 million in Q1 2020 from the same period last year, while for Mar 2020 it was $1.1 million, marking a year-over-year increase of 12635.98%. This contributed to the annual value of $1.4 million for FY2019, which is 11778.12% up from last year.
  • According to the latest figures from Q1 2020, Protagonist Therapeutics' Long-Term Deferred Tax is $1.1 million, which was up 12635.98% from $1.4 million recorded in Q4 2019.
  • In the past 5 years, Protagonist Therapeutics' Long-Term Deferred Tax ranged from a high of $2.1 million in Q3 2019 and a low of $478000.0 during Q1 2019
  • For the 3-year period, Protagonist Therapeutics' Long-Term Deferred Tax averaged around $1.3 million, with its median value being $1.3 million (2019).
  • Per our database at Business Quant, Protagonist Therapeutics' Long-Term Deferred Tax soared by 11778.12% in 2019 and then skyrocketed by 12635.98% in 2020.
  • Protagonist Therapeutics' Long-Term Deferred Tax (Quarter) stood at $658000.0 in 2018, then surged by 117.78% to $1.4 million in 2019, then fell by 24.49% to $1.1 million in 2020.
  • Its Long-Term Deferred Tax was $1.1 million in Q1 2020, compared to $1.4 million in Q4 2019 and $2.1 million in Q3 2019.